Related Experiment Videos
Preemptive liver transplantation in primary hyperoxaluria type 1: timing and preliminary results
M J Kemper1, D Nolkemper, X Rogiers
1University Children's Hospital, Department of Surgery, Hamburg, Germany. kemper@uke.uni-hamburg.de
Insights
Preemptive isolated liver transplantation (PLTX) offers a cure for primary hyperoxaluria type 1 (PH1). Early PLTX in children can normalize oxalate levels and preserve kidney function, preventing end-stage renal disease.
Area of Science:
- Hepatology
- Nephrology
- Pediatric Gastroenterology
Background:
- Primary hyperoxaluria type 1 (PH1) is a rare genetic disorder causing excessive oxalate production.
- The metabolic defect in PH1 can be cured by liver transplantation.
- Optimal timing for preemptive isolated liver transplantation (PLTX) in PH1 remains undefined.
Purpose of the Study:
- To evaluate the safety and efficacy of preemptive isolated liver transplantation (PLTX) in children with PH1.
- To assess the impact of PLTX on plasma and urinary oxalate levels.
- To determine the effect of PLTX on renal function in PH1 patients.
Main Methods:
- Successful PLTX performed in 4 pediatric patients (age 3-9 years) with PH1.
- Monitoring of plasma and urinary oxalate levels post-transplantation.
- Assessment of renal function, including patients with pre-existing chronic kidney disease.
Main Results:
- No mortality or procedure-related morbidity observed.
- Rapid normalization of plasma and urinary oxalate levels.
- Stable renal function maintained for over 24 months in a patient with advanced chronic renal failure.
Conclusions:
- PLTX is a safe and effective treatment for PH1 in children.
- Early consideration of PLTX is crucial to prevent or delay end-stage renal disease and systemic oxalosis.
- While individualized treatment is necessary, PLTX should be discussed proactively in PH1 management.
Abstract:
Preemptive isolated liver transplantation (PLTX) can cure the metabolic defect in primary hyperoxaluria type 1 (PH1) but there are no uniformally accepted recommendations concerning the timing of this transplantation procedure. We have performed PLTX successfully in 4 children (age 3-9 years) with PH1 with no mortality or morbidity due to the transplantation procedure. Plasma and urinary oxalate levels normalised rapidly and renal function remained stable including one patient with advanced chronic renal failure who showed a stable course for more than 24 months. Although treatment must be individualised in this severe metabolic disorder and PLTX has to be viewed as invasive procedure, we feel PLTX should be offered and discussed not too late in the treatment of PH1 to prevent or at least delay the progression to end stage renal disease and systemic oxalosis.